The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort
National Taiwan University Hospital
240 participants
Aug 1, 2021
INTERVENTIONAL
Conditions
Summary
This prospective cohort study aims to provide the evidence-based clinical guide to help decide the revaccination doses of hepatitis B vaccine that the high-risk young adults without hepatitis B seroprotective antibodies (anti-HBs titer\<10 mIU/mL) need to take.
Eligibility
Inclusion Criteria6
- The actual age at the time of admission was higher than 20 years old and birth year after 1987
- Born in Taiwan and had received a full course of hepatitis B vaccines at least three doses at infant period.
- Those who have tested negative for hepatitis B surface antibody and surface antigen at baseline
- Have never been vaccinated against hepatitis B in childhood and adolescence by questionnaire
- Consent to administer 1-2 doses of hepatitis B vaccine according to the assigned group after sharing decision making process
- In good health
Exclusion Criteria3
- Those who were previously allergic to hepatitis B vaccine or its components (such as yeast)
- Those who have been vaccinated against hepatitis B during childhood and adolescence
- Those who have a positive test for hepatitis B surface antibody or a positive test for hepatitis B surface antigen
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04970836